Compare Novo Nordisk A/S (NVO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Revvity Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Revvity Inc trades at $110.7 (market cap $11.87B). The key difference: Novo Nordisk A/S is far larger — about 18.6× Revvity Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RVTY | |
|---|---|---|
Market Cap | $220.53B | $11.87B |
Sector | Health | Technology |
52-Week High | $71.70 | $117.75 |
52-Week Low | $35.29 | $82.26 |
Enterprise Value | $239.49B | $14.36B |
Dividend Yield | 3.63% | 0.26% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
